TY - JOUR
T1 - Occurrence and Prognostic Relevance of CD30 Expression in Post-transplant Lymphoproliferative Disorders
AU - Vase, Maja Ølholm
AU - Maksten, E.F.
AU - Bendix, K.
AU - Hamilton-Dutoit, S.
AU - Andersen, C.
AU - Moller, M.B.
AU - Sorensen, S.S.
AU - Jespersen, B.
AU - Kampmann, J.
AU - Sondergard, E.
AU - Nielsen, P.S.
AU - D'Amore, F.
PY - 2015
Y1 - 2015
N2 - Abstract Posttransplant lymphoproliferative disorders (PTLDs) are potentially fatal, often Epstein-Barr virus (EBV)-driven neoplasias developing in immunocompromised hosts. Initial treatment usually consists of a reduction in immunosuppressive therapy and/or rituximab with or without chemotherapy. However, patients who relapse do poorly and new treatment options are warranted. With the introduction of the immunoconjugate brentuximab vedotin, the CD30 antigen has become an effectively targetable molecule. Therefore, we investigated the frequency and level of CD30 expression in PTLDs. We identified 108 PTLD patients diagnosed during 1994-2011, of which 62 had adequate paraffin embedded tissue for tissue microarray construction. Immunohistochemical expression of CD30 was consistently detected in all types of PTLD (overall 85.25%), including the monomorphic subtypes, and was correlated to a more favorable outcome. For diffuse large B-cell lymphoma (DLBCL)-type PTLD this was regardless of EBV-status, and remained significant in multivariate analyses. Cell-of-origin had no independent prognostic value in our series of DLBCL PTLD
AB - Abstract Posttransplant lymphoproliferative disorders (PTLDs) are potentially fatal, often Epstein-Barr virus (EBV)-driven neoplasias developing in immunocompromised hosts. Initial treatment usually consists of a reduction in immunosuppressive therapy and/or rituximab with or without chemotherapy. However, patients who relapse do poorly and new treatment options are warranted. With the introduction of the immunoconjugate brentuximab vedotin, the CD30 antigen has become an effectively targetable molecule. Therefore, we investigated the frequency and level of CD30 expression in PTLDs. We identified 108 PTLD patients diagnosed during 1994-2011, of which 62 had adequate paraffin embedded tissue for tissue microarray construction. Immunohistochemical expression of CD30 was consistently detected in all types of PTLD (overall 85.25%), including the monomorphic subtypes, and was correlated to a more favorable outcome. For diffuse large B-cell lymphoma (DLBCL)-type PTLD this was regardless of EBV-status, and remained significant in multivariate analyses. Cell-of-origin had no independent prognostic value in our series of DLBCL PTLD
KW - therapy
U2 - 10.3109/10428194.2014.966242
DO - 10.3109/10428194.2014.966242
M3 - Journal article
C2 - 25248878
VL - 56
SP - 1677
EP - 1685
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 6
ER -